Strategic selection and development of immunogenicity binding methods

Bioanalysis

Volumn 4, Issue 12, 2012, Pages 1491-1508

  Menendez, Ana T ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PANITUMUMAB; RUTHENIUM; STREPTAVIDIN; TOCILIZUMAB;

ACCURACY; ANTIBODY DETECTION; ANTIBODY LABELING; ANTIGEN BINDING; BINDING AFFINITY; BINDING KINETICS; BIOTINYLATION; CONCENTRATION (PARAMETERS); CONFORMATIONAL TRANSITION; DRUG LABELING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; HUMAN; IMMUNOGENICITY; LIMIT OF QUANTITATION; MATERIAL COATING; MOLECULAR INTERACTION; NONHUMAN; PRACTICE GUIDELINE; PROCESS OPTIMIZATION; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

EID: 84863964433     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.114     Document Type: Review

References (45)

1. Menendez AT. Toxic effects of immunogenicity to biopharmaceuticals. In: Cobert's Manual of Drug Safety and Pharmacovigilance (Second Edition). Cobert BL (Ed.). Jones & Bartlett Publishers, MA, USA, Chapter 46, 317-320 (2011).
2. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348(7), 601-608 (2003).
3. Subramanyam M. Case Study: immunogenicity of natalizumab. In: Immunogenicity of Biopharmaceuticals (1st Edition). Van de Wert M, Moller EH (Eds). Springer AAPS Press, NY, USA, Chapter 10, 173-187 (2008).
4. Haggerty HG, Abbott MA, Reilly TP et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J. Rheumatol. 34 (12), 2365-2373 (2007).
5. EMA. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Committee for Proprietary Medicinal Products (CPMP), (2008).
6. EMA. Draft guideline on immunogenicity assessment of monoclonalantibodies intended for in vivo clinical use. Committee for Medicinal Products for Human Use (CMPH) (2010).
7. Shankara G, Devanarayan V, Amaravadic L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharma. Biomed. Analysis 48(5), 1267-1281 (2008).
8. US FDA. Draft guidance for industry. Assay development for immunogenicity testing of therapeutic proteins (2009).
9. Swann PG, Shapiro MA. Regulatory considerations for development of bioanalytical assays for biotechnology products. Bioanalysis 3(6), 597-603 (2011).
10. Koren E, Holly HW, Shores E et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333, 1-9 (2008
11. Jahn EM, Schneider CK, How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations. Nat. Biotechnol. 25(5), 280-286 (2009).
12. Buttel IC, Chamberlain P, Chowers Y et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39, 100-109 (2011).
13. Pendley C, Shankar G, Bioanalytical interferences in immunoassays for antibody biotherapeutics. Bioanalysis 3(7), 703-706 (2011).
14. Gorovits B. Antidrug antibody assay validation: industry results. AAPS J. 11, 133-138 (2009).
15. Bautista AC, Wullner D, Moxness M et al. Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment. Bioanalysis 2(4), 721-731 (2010).
16. Mikulskis A, Yeung D, Subramanyam M, Amaravadi L. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. J. Immunol. Methods 365, 38-49 (2011).
17. Mora JR, Obenauer-Kutner L, Patel V. Application of the Gyrolab platform to ligand-binding assays: a user's perspective. Bioanalysis 2(10), 1711-1715 (2010).
18. Logfren JA, Dhandapani S, Pennucci JF et al. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J. Immunol. 178, 7467-7472 (2007).
19. Sickert D, Kroeger, K, Chokote E et al. Improvement of drug tolerance in immunogenicity testing by Biacore. J. Immunol. Methods 334, 29-36 (2008).
20. Weeraratne D, Chen A, Pennucci JJ et al. Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin. Pharmacol. 11, 17 (2011).
21. Wang H, Shi J, Wang Q et al. Assessment of the pre-clinical immunogenicity of new VEGF receptor Fc-fusion protein with ELISA and Biacore. Cancer Immunol. Immunother. 59, 239-246 (2010).
22. Stubenrauch K, Wessels U, Vogel R, Schleypen J. Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies by surrogate standards. Anal. Biochem. 390(2), 188-196 (2009).
23. Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin. Ther. 32(9), 1597-1609 (2010).
24. Barger TE, Kuck AJ, Chirmule N, Swanson SJ, Mytych DT. Detection of anti- ESA antibodies in human samples from PRCA and non-PRCA patients: an immunoassay platform comparison. Nephrol. Dial. Transplant. 227(2), 688-693 (2012).
25. Li J, Schantz A, Schwegler M, Shankar G. Detection of low affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet® biolayer interferometery. J. Pharm. Biomed. Anal. 54, 286-944 (2011).
26. Neubert H, Grace C, Rumpel K, James I. Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry. Anal. Chem. 80, 6907-6914, (2008).
27. Pan J, Small T, Qin D et al. Comparison of the NIDS® rapid assay with ELISA methods in immunogenicity testing of two biotherapeutics. Pharmacol. Toxicol. Methods 63(2), 150-159 (2011).
28. Crisino RM, Dulanto B. Bioanalysis-related highlights from the 2011 AAPS National Biotechnology Conference: Conference Report & Analysis. Imperacer, Nano- Intelligent Detection System (NIDS). Bioanalysis 3(16), 1809-1814 (2011).
29. Spengler M, Adler M, Jonas A, Niemeyer CM. Immuno-PCR assays for immunogenicity testing. Biochem. Biophys. Res. Commun. 387(2) 278-281 (2009).
30. Yohrling J. Ligand-binding assays: risk of using a platform supported by a single vendor. Bioanalysis 1(3), 629-636 (2009).
31. Mire-Sluis A, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289, 1-16 (2004).
32. Patton A, Mullenix MC, Swanson SJ, Koren E. An acid dissociation bridging ELISA for detection of antibodies against therapeutic proteins in the presence of antigen. J. Immunol. Methods 304, 189-195 (2005).
33. Smith HW, Butterfield A, Sun D. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Reg. Toxicol. Pharmacol. 49, 230-237 (2007).
34. Butterfield AM, Chain JS, Ackermann BL, Konrad RJ. Comparison of assay formats for drug-tolerant immunogenicity testing. Bioanalysis 2(12), 1961-1969 (2010).
35. Qiu ZJ, Ying Y, Fox M et al. A novel homogenous biotin-digoxigenin based assay for the detection of human therapeutic antibodies in autoimmune serum. J. Immunological Methods 362 (1-2), 101-111 (2010).
36. Menendez AT. Accelerating Bioassay Transfer in a GMP Environment BioProcess International. 7(11) 26-33 (2009).
37. Staack RF, Stracke JO, Stubenrauch K, Vogel R, Scheleypen J, Papadimitriou A. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. Bioanalysis 3(5), 523-534 (2011).
38. Menendez AT, Ritter N, Zmuda J, Jani D, Goyal J. Recommendations for cell banks used in GXP assays. Bioprocess International 10(1), 27-40 (2012).
39. Barger TE, Zhou L, Hale M, Moxness M, Swanson SJ, Chirmule N. Comparing exponentially weighted moving average and run rules in process control of semiquantitative immunogenicity immunoassays. AAPS J. 12(1), 79-86 (2009).
40. Zhong ZD, Dinnogen S, Hokom M et al. Identification and inhibition of drug target interference in immunogenicity assays. J. Immunol. Methods 355, 21-28 (2010).
41. Hammond O, Reynolds J, Rubinstein LJ, Sikkema D, Marchese RD. Complexities of clinical assay development and optimization prior to first-in-man immunization trials - a description of immunogenicity assay development for the testing of samples from a phase 1 Alzheimer's vaccine trial. J. Immunoassay Immunochem. 29 (4), 332-347 (2008).
42. Gorovits B. Immunogenicity: prediction, detection and effective assay development. Bioanalysis 2(9), 1539-6180 (2010
43. Oldfield P. Differences in bioanalytical method validation for biologically derived macromolecules (biosimilars) compared with small molecules (generics). Bioanalysis 3(14), 1551-1553 (2011).
44. Smith HW, Moxness M, Marsden R. Summary of confirmation cut point discussions. AAPS J. 13(2), 227-229 (2011).
45. Swanson SJ, Chirmule N. Assessing specificity for immunogenicity assays. Bioanalysis 1(3), 611-617 (2009